Waning Time of Maternally Derived Anti-Hepatitis A and Anti-Varicella Zoster Virus Antibodies

Güzelküçük, Zeliha; Çamurdan, Aysu Duyan; Beyazova, Ufuk; Bozdayı, Gülendam; Civil, Fusun; Altay-Kocak, Aylin

doi:10.1055/s-0038-1677484

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from southern Turkey declared that the infants had detectable amount of antibodies till 12 months, but the seropositivity rate was 36.1% although 93.9% of the mothers had immunity (Derya, Necmi, Emre, & Akgun, 2005). Another report established the rate of seropositivity to be 29.6% and 14.8% in 12 th and 18 th months (Guzelkucuk et al, 2019). The rate of immunity before the first dose of the vaccine was 40.4% (n=21) in our study and median age of the seronegative participants was 14 months.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of the Rate of Hepatitis a Immunity in a Small City After the Vaccination Program: One Center Experience

Celep

ÖZÇELİK²,

EVSİLE³

2023

Sabuncuoglu Serefeddin Health Sciences

View full text Add to dashboard Cite

Purpose: Hepatitis A is an infectious disease caused by hepatitis A virus (HAV). Symptomatic infection causes health care costs with loss of labor and school time. HAV outbreaks may cause economic problems by disrupting trade and tourism. The aim of this study is to determine the rate of immunity against HAV infection in a sample of pediatric population. Methods: The study group consisted of all children who underwent anti-HAV IgG evaluation for any reason between January 1, 2012 and December 31, 2020. The data about age, date of birth, sex, residence, vaccination status were retrospectively collected from the hospital record system. Anti-HAV IgG status was determined by chemiluminescent microparticle immunassay kits. The statistical analyses were presented with descriptive methods. Results: Overall 1189 children aged 1-17 years old enrolled to the study. The rate of anti HAV IgG seropositivity was 41.2% in the whole study group. The rates of completed vaccination scheme and seropositivity were 10.7% and 92.2%. Natural immunity rate was 32.6%. Conclusion: The 7-17 age group was found to be susceptible to the acute infection, they were considered as the new target population of vaccination. Vaccination seemed to be the most effective way of providing seropositivity to get rid of acute infection risk and eliminating geographic and socioeconomic differences.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluation of the Rate of Hepatitis a Immunity in a Small City After the Vaccination Program: One Center Experience

Celep

ÖZÇELİK²,

EVSİLE³

2023

Sabuncuoglu Serefeddin Health Sciences

View full text Add to dashboard Cite

show abstract

Modelling the cost-effectiveness of hepatitis A vaccination in South Africa

Patterson¹,

Cleary²,

Zyl³

et al. 2022

Preprint

View full text Add to dashboard Cite

The World Health Organization (WHO) recommends the consideration of introducing routine hepatitis A vaccination into national immunization schedules for children younger than 1 year old in countries with intermediate HAV endemicity. Recent data suggest that South Africa is transitioning from high to intermediate HAV endemicity, thus it is important to consider the impact and cost of potential routine hepatitis A vaccination strategies in the country. An age-structured compartmental model of hepatitis A transmission was calibrated with available data from South Africa, incorporating direct costs of hepatitis A treatment and vaccination. We used the calibrated model to evaluate the impact and costs of several childhood hepatitis A vaccination scenarios from 2023 to 2030. We assessed how each scenario impacted the burden of hepatitis A (symptomatic hepatitis A cases and mortality) as well as calculated the incremental cost per DALY averted as compared to the South African cost-effectiveness threshold. All costs and outcomes were discounted at 5%. For the modelled scenarios, the median estimated cost of the different vaccination strategies ranged from $1.71 billion to $2.85 billion over the period of 2023 to 2030, with the cost increasing for each successive scenario and approximately 39-52% of costs being due to vaccination. Scenario 1, which represented the administration of one dose of the hepatitis A vaccine in children < 2 years old, requires approximately 5.3 million vaccine doses over 2023-2030 and is projected to avert a total of 136,042 symptomatic cases [IQR: 88,842-221,483] and 31,106 [IQR: 22,975- 36,742] deaths due to hepatitis A over the period of 2023 to 2030. The model projects that Scenario 1 would avert 8,741 DALYs over the period of 2023 to 2030, however is not cost-effective against the South African cost-effectiveness threshold with an ICER per DALY averted of $21,006. While Scenario 3 and 4 included the administration of more vaccine doses and averted more symptomatic cases of hepatitis A, these scenarios were absolutely dominated owing to the population being infected before vaccination through the mass campaigns at older ages. The model was highly sensitivity to varying access to liver transplant in South Africa. When increasing the access to liver transplant to 100% for baseline and Scenario 1, the ICER for Scenario 1 becomes cost-effective against the CET (ICER = $2,425). Given these findings, we recommend further research is conducted to understand the access to liver transplants in South Africa to better estimate the cost of liver transplant care for hepatitis A patients. The modelling presented in this paper has been used to develop a user-friendly application for vaccine policy makers to further interrogate the model outcomes and consider the costs and benefits of introducing routine hepatitis A vaccination in South Africa.

show abstract

Modelling the Cost-Effectiveness of Hepatitis A in South Africa

Patterson,

Cleary,

Norman

et al. 2024

Vaccines

View full text Add to dashboard Cite

The World Health Organization (WHO) recommends the consideration of introducing routine hepatitis A vaccination into national immunization schedules for children ≥ 1 years old in countries with intermediate HAV endemicity. Recent data suggest that South Africa is transitioning from high to intermediate HAV endemicity, thus it is important to consider the impact and cost of potential routine hepatitis A vaccination strategies in the country. An age-structured compartmental model of hepatitis A transmission was calibrated with available data from South Africa, incorporating direct costs of hepatitis A treatment and vaccination. We used the calibrated model to evaluate the impact and costs of several childhood hepatitis A vaccination scenarios from 2023 to 2030. We assessed how each scenario impacted the burden of hepatitis A (symptomatic hepatitis A cases and mortality) as well as calculated the incremental cost per DALY averted as compared to the South African cost-effectiveness threshold. All costs and outcomes were discounted at 5%. For the modelled scenarios, the median estimated cost of the different vaccination strategies ranged from USD 1.71 billion to USD 2.85 billion over the period of 2023 to 2030, with the cost increasing for each successive scenario and approximately 39–52% of costs being due to vaccination. Scenario 1, which represented the administration of one dose of the hepatitis A vaccine in children < 2 years old, requires approximately 5.3 million vaccine doses over 2023–2030 and is projected to avert a total of 136,042 symptomatic cases [IQR: 88,842–221,483] and 31,106 [IQR: 22,975–36,742] deaths due to hepatitis A over the period of 2023 to 2030. The model projects that Scenario 1 would avert 8741 DALYs over the period of 2023 to 2030; however, it is not cost-effective against the South African cost-effectiveness threshold with an ICER per DALY averted of USD 21,006. While Scenario 3 and 4 included the administration of more vaccine doses and averted more symptomatic cases of hepatitis A, these scenarios were absolutely dominated owing to the population being infected before vaccination through the mass campaigns at older ages. The model was highly sensitive to variation of access to liver transplant in South Africa. When increasing the access to liver transplant to 100% for the baseline and Scenario 1, the ICER for Scenario 1 becomes cost-effective against the CET (ICER = USD 2425). Given these findings, we recommend further research is conducted to understand the access to liver transplants in South Africa and better estimate the cost of liver transplant care for hepatitis A patients. The modelling presented in this paper has been used to develop a user-friendly application for vaccine policy makers to further interrogate the model outcomes and consider the costs and benefits of introducing routine hepatitis A vaccination in South Africa.

show abstract

Waning Time of Maternally Derived Anti-Hepatitis A and Anti-Varicella Zoster Virus Antibodies

Cited by 3 publications

References 23 publications

Evaluation of the Rate of Hepatitis a Immunity in a Small City After the Vaccination Program: One Center Experience

Evaluation of the Rate of Hepatitis a Immunity in a Small City After the Vaccination Program: One Center Experience

Modelling the cost-effectiveness of hepatitis A vaccination in South Africa

Modelling the Cost-Effectiveness of Hepatitis A in South Africa

Contact Info

Product

Resources

About